Geode Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.5M Sell
708,490
-8,940
-1% -$62K ﹤0.01% 2911
2026
Q2
$5.28M Buy
717,430
+50,083
+8% +$480K ﹤0.01% 2883
2026
Q1
$8.42M Buy
667,347
+27,400
+4% +$314K ﹤0.01% 2471
2025
Q4
$6.58M Sell
639,947
-5,172
-0.8% -$43.6K ﹤0.01% 2620
2025
Q3
$3.74M Buy
645,119
+13,565
+2% +$79.4K ﹤0.01% 2929
2025
Q2
$4.24M Buy
631,554
+42,479
+7% +$342K ﹤0.01% 2812
2025
Q1
$5.33M Buy
589,075
+15,184
+3% +$189K ﹤0.01% 2623
2024
Q4
$9.9M Sell
573,891
-2,560
-0.4% -$46.4K ﹤0.01% 2376
2024
Q3
$9.21M Buy
576,451
+46,512
+9% +$733K ﹤0.01% 2433
2024
Q2
$7.55M Buy
529,939
+54,581
+11% +$776K ﹤0.01% 2496
2024
Q1
$6.74M Buy
475,358
+15,977
+3% +$226K ﹤0.01% 2543
2023
Q4
$6.93M Buy
459,381
+20,800
+5% +$308K ﹤0.01% 2535
2023
Q3
$6.93M Buy
438,581
+37,950
+9% +$598K ﹤0.01% 2471
2023
Q2
$6.07M Buy
400,631
+216,841
+118% +$2.99M ﹤0.01% 2583
2023
Q1
$2.66M Buy
183,790
+1,833
+1% +$24.5K ﹤0.01% 2913
2022
Q4
$2.46M Buy
181,957
+14,839
+9% +$260K ﹤0.01% 2963
2022
Q3
$2.63M Buy
167,118
+65,347
+64% +$830K ﹤0.01% 2989
2022
Q2
$1.24M Sell
101,771
-75,962
-43% -$576K ﹤0.01% 3322
2022
Q1
$1.67M Buy
177,733
+15,546
+10% +$167K ﹤0.01% 3350
2021
Q4
$2.78M Buy
+162,187
New +$3.93M ﹤0.01% 3206

Other funds holding TRDA

Geode Capital Management's TRDA Position: Q3 2026 in Review

Geode Capital Management reduced its Entrada Therapeutics (TRDA) stake by 1.2% in Q3 2026, selling an estimated $62K and leaving 708,490 shares worth $4.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Geode Capital Management first reported a position in TRDA in Q4 2021 and has held it in 20 quarters since. The position peaked at $9.9M in Q4 2024. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Geode Capital Management held 708,490 shares of Entrada Therapeutics worth $4.5M as of Q3 2026.
  • Geode Capital Management sold 8,940 Entrada Therapeutics shares in Q3 2026, an estimated $62K.
  • Entrada Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2911 holding.
  • Geode Capital Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • Geode Capital Management's Entrada Therapeutics position peaked at $9.9M in Q4 2024.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.